


LPA2 antagonist 1

Cat. No.:	HY-18075		
CAS No.:	1017606-66-4		
Molecular Formula:	C ₂₀ H ₂₃ Cl ₂ N ₅ O ₂ S ₂		
Molecular Weight:	500.46		
Target:	LPL Receptor		
Pathway:	GPCR/G Protein		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (199.82 mM)
 DMF : ≥ 100 mg/mL (199.82 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9982 mL	9.9908 mL	19.9816 mL
	5 mM	0.3996 mL	1.9982 mL	3.9963 mL
	10 mM	0.1998 mL	0.9991 mL	1.9982 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: 2.5 mg/mL (5.00 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	LPA2 antagonist 1 is a LPA2 antagonist with an IC ₅₀ of 17 nM.
IC₅₀ & Target	IC ₅₀ : 17 nM (LPA2) ^[1]
In Vitro	LPA2 antagonist 1 inhibits the phosphorylation of Erk induced by LPA in a concentration dependent manner. LPA2 antagonist 1 inhibits HCT-116 colon cancer cell proliferation caused by LPA in a doses dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Cell Mol Life Sci. 2020 May 28.
- Vet Microbiol. 2021, 109177.
- Research Square Preprint. 2021 Aug.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Beck HP, et al. Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA